Jun 21, 2022 / 01:00PM GMT
Joe Diaz - Lytham Partners - Managing Partner
Hello, everyone, and thank you for participating in the Lytham Partners 2022 Summer Investor Conference. My name is Joe Diaz. I'm a Managing Partner at Lytham Partners. For this presentation, we welcome Humanigen, which trades on the NASDAQ exchange under the ticker symbol, HGEN. Representing Humanigen today is Dr. Dale Chappell, Chief Scientific Officer.
Dale and I will engage in a fireside Q-and-A chat today. We will discuss Humanigen's drug candidate, lenzilumab, which is designed to neutralize the cytokine storm associated with COVID-19 and other indications. We will also bring you up to date on the status of the drug approval process through the NIH and the FDA.
Before we begin our discussion, we thank all of you for participating today. Lytham Partners is one of the country's leading investor relations firm. With more than two decades of corporate access experience, we've built one of the industry's most diverse and effective platforms for connecting small-cap companies with high-quality and focused institutional investors.
Humanigen Inc at Lytham Partners Summer Investor Conference (Virtual) Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers